Diagnosing Myelofibrosis

Information on myelofibrosis criteria.


A comprehensive program created by Incyte to connect both physicians and myelofibrosis patients to access, reimbursement, education and support for Jakafi® (ruxolitinib).

Join Today

Become a member of Jakafi.com and gain access to member-only benefits.

Jakafi® (ruxolitinib) for intermediate or high-risk myelofibrosis

Jakafi® (ruxolitinib) is an oral JAK1 and JAK2 inhibitor treatment indicated for patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post–polycythemia vera myelofibrosis and post–essential thrombocythemia myelofibrosis—collectively known as myelofibrosis diseases.1 Learn more about myelofibrosis treatment with Jakafi® (ruxolitinib).

COMFORT-I = COntrolled MyeloFibrosis study with ORal JAK inhibitor Treatment (I).


  1. Jakafi Prescribing Information. Incyte Corporation.